ArticleFrontiers in nutrition2026
Dynamic vitamin D trajectories and their prognostic value in breast cancer: a group-based trajectory modeling study.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer represents the most frequently diagnosed malignancy and a leading cause of cancer-related mortality among women globally, with substantial prognostic heterogeneity that underscores the urgent need for robust prognostic biomarkers to guide personalized clinical management. Although accumulating evidence has linked vitamin D status to breast cancer progression, most existing studies have relied on static single measurements of serum vitamin D, leading to inconsistent findings, while the prognostic implications of dynamic longitudinal changes in vitamin D levels during treatment and follow-up remain largely underexplored. In this retrospective cohort study, we enrolled 513 female patients with pathologically confirmed primary invasive breast cancer treated between 2020 and 2023, with a median follow-up duration of 38.0 months. Serial serum 25-hydroxyvitamin D measurements were obtained at three predefined time points: baseline, mid-treatment, and post-treatment follow-up. Group-based trajectory modeling (GBTM) was employed to identify distinct latent subgroups with homogeneous vitamin D change patterns. We then evaluated the association between these trajectories and event-free survival (EFS) using Kaplan-Meier analysis, log-rank test, and multivariable Cox regression, and further constructed a trajectory-based risk stratification model and a visual prognostic nomogram, whose performance was validated via concordance index (C-index), calibration curves, and decision curve analysis. We identified 6 distinct vitamin D trajectories, which were further categorized into three risk strata, with 64.9% of patients presenting with severe vitamin D deficiency at baseline. After multivariable adjustment for established clinical factors, dynamic vitamin D trajectories were confirmed as an independent prognostic factor for EFS: patients in the high-risk group (characterized by persistent deficiency or worsening vitamin D status) exhibited significantly worse survival outcomes compared with the low-risk group with consistently sufficient vitamin D levels (all pairwise
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.